Edit This Favorite

In late December, NPS Pharmaceuticals, Inc., announced that the U.S. Food and Drug Administration (FDA) has approved Gattex (teduglutide [rDNA origin]) for injection for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support. Gattex, which will be available in the first quarter of 2013, is a major treatment advance for SBS.

The Oley Foundation encourages research and development of new drugs, products, and services that may improve the health and well-being of our members. We hope this new treatment will reduce the challenges presented by short bowel syndrome/intestinal failure.

For more on Gattex (including the risks), go to gattex.com (an NPS Web site) or watch for an article in an upcoming issue of the Oley newsletter.

This website is an educational resource. It is not intended to provide medical advice or recommend a course of treatment. You should discuss all issues, ideas, suggestions, etc. with your clinician prior to use. Clinicians in a relevant field have reviewed the medical information; however, the Oley Foundation does not guarantee the accuracy of the information presented, and is not liable if information is incorrect or incomplete. If you have questions please contact Oley staff.

Updated in 2015 with a generous grant from Shire, Inc.

This website was updated in 2015 with a generous grant from Shire, Inc. This website is an educational resource. It is not intended to provide medical advice or recommend a course of treatment. You should discuss all issues, ideas, suggestions, etc. with your clinician prior to use. Clinicians in a relevant field have reviewed the medical information; however, the Oley Foundation does not guarantee the accuracy of the information presented, and is not liable if information is incorrect or incomplete. If you have questions please contact Oley staff.